Rosetta expands into China with cancer Dx licensing deal, but cuts jobs at home
This article was originally published in Clinica
Executive Summary
Israeli molecular diagnostics specialist Rosetta Genomics' microRNA-based tests will soon be available in China, after the company signed an exclusive distribution agreement with Avatao Biotech. However, the good news was eclipsed by Rosetta's announcement that it will cut 35 jobs in Israel – well over 50% of its entire workforce – to halve its monthly cash burn.